Investor Seeks Initial Approval Of $1.4M Class Settlement With Drug Maker
MIAMI — The lead plaintiff in a securities class action against a clinical-stage biopharmaceutical company, certain of its officers and managers and underwriters of the company’s initial public offering (IPO) asked...To view the full article, register now.
Already a subscriber? Click here to view full article